Erin K. Brenner - May 25, 2022 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief Product Dev. Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
May 25, 2022
Transactions value $
$15,000
Form type
4
Date filed
5/27/2022, 04:02 PM
Previous filing
Feb 18, 2022
Next filing
Dec 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Options Exercise $15K +15K $1.00* 15K May 25, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Options Exercise -15K -12.48% 105K May 25, 2022 Common Stock 15K $1.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested on July 16, 2019 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
F2 Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 81,659 shares of common stock of Private Pear for $1.46 per share.